{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:09:18Z","timestamp":1778720958557,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["A1-U24\\u2013205-020404"],"award-info":[{"award-number":["A1-U24\\u2013205-020404"]}],"id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109893","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:14:07Z","timestamp":1776467647000},"page":"109893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and anti-bladder cancer activity of novel dihydroartemisinin-ibuprofen hybrids"],"prefix":"10.1016","volume":"176","author":[{"given":"Hui","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Along","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingke","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Typhaine","family":"Bejoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peike","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109893_bb0005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.3887571","article-title":"Qinghaosu (artemisinin): an antimalarial drug from China","volume":"228","author":"Klayman","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109893_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115000","article-title":"A comprehensive overview of artemisinin and its derivatives as anticancer agents","volume":"247","author":"Zeng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109893_bb0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.7150\/ijbs.50364","article-title":"Dihydroartemisinin: a potential natural anticancer drug","volume":"17","author":"Dai","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2026.109893_bb0020","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/acsinfecdis.3c00031","article-title":"Dihydroartemisinin disrupts zinc homeostasis in plasmodium falciparum to potentiate its antimalarial action via pyknosis","volume":"9","author":"Asahi","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.109893_bb0025","doi-asserted-by":"crossref","first-page":"11704","DOI":"10.1038\/s41598-024-62126-8","article-title":"Dihydroartemisinin-driven selective anti-lung cancer proliferation by binding to EGFR and inhibition of NRAS signaling pathway-induced DNA damage","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109893_bb0030","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8191","article-title":"Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response-induced upregulation of CHAC1 expression","volume":"46","author":"Wang","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2026.109893_bb0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1142\/S0192415X23500234","article-title":"Dihydroartemisinin affects STAT3\/DDA1 signaling pathway and reverses breast cancer resistance to cisplatin","volume":"51","author":"Zhang","year":"2023","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.bioorg.2026.109893_bb0040","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.7150\/thno.55939","article-title":"Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer","volume":"11","author":"Bai","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.109893_bb0045","doi-asserted-by":"crossref","first-page":"38832","DOI":"10.1021\/acsomega.2c04562","article-title":"Synthesis and antitumor activities of novel mitochondria-targeted dihydroartemisinin ether derivatives","volume":"7","author":"Xu","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.109893_bb0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2165\/00003495-198427030-00004","article-title":"Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use","volume":"27","author":"Hart","year":"1984","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109893_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25063558","article-title":"Design, synthesis, anti-inflammatory activity, DFT modeling and docking study of new ibuprofen derivatives","volume":"25","author":"Abbas","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109893_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108506","article-title":"Discovery and optimization of ibuprofen derivatives as the NF-\u03baB\/iNOS pathway inhibitors for the treatment of ulcerative colitis","volume":"161","author":"Lin","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109893_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.550","article-title":"Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70","volume":"5","author":"Endo","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.109893_bb0070","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41416-020-0906-7","article-title":"Ibuprofen mediates histone modification to diminish cancer cell stemness properties via a COX2-dependent manner","volume":"123","author":"Shen","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109893_bb0075","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/cncr.33623","article-title":"Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO cancer screening trial","volume":"127","author":"Chudy-Onwugaje","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.109893_bb0080","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s11030-022-10551-0","article-title":"Novel 1,2,4-triazoles derived from ibuprofen: synthesis and in vitro evaluation of their mPGES-1 inhibitory and antiproliferative activity","volume":"27","author":"B\u00fclb\u00fcl","year":"2022","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.109893_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2024.112596","article-title":"Design, synthesis, and antitumor mechanism investigation of iridium(III) complexes conjugated with ibuprofen","volume":"257","author":"Chen","year":"2024","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bioorg.2026.109893_bb0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice","volume":"20","author":"van Hoogstraten","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109893_bb0095","doi-asserted-by":"crossref","unstructured":"F. Bray, M. Laversanne, H. Sung, et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 74 (2024) 229\u2013263, doi:https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"10.1016\/j.bioorg.2026.109893_bb0100","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.109893_bb0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: A systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bioorg.2026.109893_bb0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.NURSE.0001007608.96581.fa","article-title":"Bladder cancer: an update","volume":"54","author":"Pullen","year":"2024","journal-title":"Nursing"},{"key":"10.1016\/j.bioorg.2026.109893_bb0115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.euf.2023.03.017","article-title":"Bladder cancer carcinogens: opportunities for risk reduction","volume":"9","author":"Gaffney","year":"2023","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.bioorg.2026.109893_bb0120","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41586-025-09521-x","article-title":"Sex and smoking bias in the selection of somatic mutations in human bladder","volume":"647","author":"Calvet","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109893_bb0125","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bioorg.2026.109893_bb0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.omtn.2022.10.001","article-title":"Epigenetic regulation of MIR145 core promoter controls miR-143\/145 cluster in bladder cancer progression and treatment outcome","volume":"30","author":"Pilala","year":"2022","journal-title":"Mol. Ther. Nucleic. Acids."},{"key":"10.1016\/j.bioorg.2026.109893_bb0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2022.01.075","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Moschini","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109893_bb0140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.bioorg.2026.109893_bb0145","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ccell.2025.02.006","article-title":"CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety","volume":"43","author":"Palmer","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109893_bb0150","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2015.08.082","article-title":"CDK4\/6 inhibition controls proliferation of bladder cancer and transcription of RB1","volume":"195","author":"Sathe","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.bioorg.2026.109893_bb0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","article-title":"Targeting CDK4\/6 in breast cancer","volume":"57","author":"Shanabag","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.109893_bb0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11427-021-2140-8","article-title":"Overexpressed cyclin d1 and CDK4 proteins are responsible for the resistance to CDK4\/6 inhibitor in breast cancer that can be reversed by PI3K\/mTOR inhibitors","volume":"66","author":"Cai","year":"2022","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.bioorg.2026.109893_bb0165","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s44318-025-00371-x","article-title":"Pharmacological CDK4\/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer","volume":"44","author":"Nehme","year":"2025","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.109893_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110624","article-title":"CDK2 and CDK4 targeted liensinine inhibits the growth of bladder cancer t24 cells","volume":"382","author":"Jiang","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.109893_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117313","article-title":"Anti-tumor effects of artemisinin-based oligomers: from monomer to trimer as a novel drug-enhancing strategy","volume":"287","author":"Jiang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109893_bb0180","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pharmthera.2013.12.001","article-title":"Artemisinins: pharmacological actions beyond anti-malarial","volume":"142","author":"Ho","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109893_bb0185","doi-asserted-by":"crossref","unstructured":"Richard K. Haynes, H.-W. Chan, M.-K. Cheung, et al., C-10 ester and ether derivatives of dihydroartemisinin \u2212 10-\u03b1 artesunate, preparation of authentic 10-\u03b2 artesunate, and of other ester and ether derivatives bearing potential aromatic intercalating groups at C-10, Eur. J. Org. Chem. 2002 (2002) 113\u2013132, doi:https:\/\/doi.org\/10.1002\/1099-0690(20021)2002:1%3C113::AID-EJOC113%3E3.0.CO;2-N.","DOI":"10.1002\/1099-0690(20021)2002:1<113::AID-EJOC113>3.0.CO;2-N"},{"key":"10.1016\/j.bioorg.2026.109893_bb0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1021\/np9605495","article-title":"Stereochemistry-dependent cytotoxicity of some artemisinin derivatives","volume":"60","author":"Beekman","year":"1997","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2026.109893_bb0195","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.62347\/KHCC9690","article-title":"ITM2A inhibits the progression of bladder cancer by downregulating the phosphorylation of STAT3","volume":"14","author":"Jiang","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109893_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122643","article-title":"Artesunate impairs growth in cisplatin-resistant bladder cancer cells by cell cycle arrest, apoptosis and autophagy induction","volume":"9","author":"Zhao","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.109893_bb0205","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev.physiol.60.1.601","article-title":"Cell cycle regulation and apoptosis","volume":"60","author":"King","year":"1998","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.bioorg.2026.109893_bb0210","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1158\/2159-8290.CD-20-1114","article-title":"RB\/E2F1 as a master regulator of cancer cell metabolism in advanced disease","volume":"11","author":"Mandigo","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109893_bb0215","article-title":"FAM83B promotes cell proliferation via regulating the expression of CDK4\/CDK6\/CCND1 complex in laryngeal squamous cell carcinoma","volume":"10","author":"Hu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2026.109893_bb0220","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.breast.2021.05.008","article-title":"The role of CDK4\/6 inhibitors in early breast cancer","volume":"58","author":"Gil-Gil","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.bioorg.2026.109893_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109893_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500300","article-title":"Design, synthesis, and antihematological tumor activity of dihydroartemisinin-loxoprofen hybrids","volume":"20","author":"Liu","year":"2025","journal-title":"ChemMedChem"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:22:56Z","timestamp":1778718176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826004293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"alternative-id":["S0045206826004293"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109893","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and anti-bladder cancer activity of novel dihydroartemisinin-ibuprofen hybrids","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109893"}}